CBIO

Crescent Biopharma, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26

Figures on this page computed 2026-11-08 13:03 UTC

Last close

13.54USD

Market data, 2026-11-06

Except where said otherwise: 10-K for 2025, filed 2026-02-26

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001628280-26-011983
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-26
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001628280-26-011983
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-07-30
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-07-30
The filing itself
-1419.6%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-011983
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
-668.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-011983
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001628280-26-011983
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-07-30
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.14 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.92x

2.74x

1.65x

n/a

0.03x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-06

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-26

Sales2.92x
Its own average over 6 years, 3.7M.
Profit2.74x
Its own average over 10 years, -56.1M.
Free cash flow1.65x
Its own average over 10 years, -43.8M.
Debtn/a
Its own average over 5 years, 2.0M.
Price0.03x
Its own average over 11 years, 462. Market data, 2026-11-06

Sales is furthest from its own average, at 2.92 times.

Sales is 2.92 times its own 6-year average; Profit is 2.74 times its own 10-year average; Free cash flow is 1.65 times its own 10-year average; Price is 0.03 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-26

Sales against its own 6-year average2.92
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-011983
Reported in
USD
The filing itself
Profit against its own 10-year average2.74
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-011983
Reported in
USD
The filing itself
Free cash flow against its own 10-year average1.65
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-011983
Reported in
USD
The filing itself
Debt against its own 5-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-011983
Reported in
USD
The filing itself
Price against its own 11-year average0.03Market data, 2026-11-06
Source
market
Taken on
2026-11-06
Reported in
USD